Prenatal Diagnosis of the Hurler Syndrome: Mucopolysaccharide Pattern in Amniotic Fluid

Omura, Kiyoshi; Higami, Shinobu; Issiki, Gen; Nishizawa, Koji; Tada, Keiya

doi:10.1620/tjem.111.87

Cited by 6 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However the method of quantitative and qualitative estimation of mucopolysaccharides in the amniotic fluid has been disappointing because of the inconsistency of results. The diagnosis of Hurler's disease has been made in several laboratories using increased levels of dermatan sulfate and heparitin sulfate as a criterion (1,8,9,13,30,34), but there were some cases where the diagnosis was missed (35).…”

Section: Cell Free Amniotic Fluidmentioning

confidence: 99%

Prenatal Diagnosis of Inborn Errors of Metabolism

Matalon

1976

International Journal of Gynecology & Obstetrics

View full text Add to dashboard Cite

More than 50 inborn errors of metabolism can be diagnosed in the fetus. This is accomplished by evaluation of constituents of the cell free amniotic fluid or of cultured or uncultured amniotic fluid cells. Only those syndromes with specific abnormal contributions to amniotic fluid can be so diagnosed. Currently diagnosable diseases and their assay methods are reviewed. Such assay methods must be able to differentiate the unaffected heterozygote from the affected homozygote.

show abstract

Section: Cell Free Amniotic Fluidmentioning

confidence: 99%

Prenatal Diagnosis of Inborn Errors of Metabolism

Matalon

1976

International Journal of Gynecology & Obstetrics

View full text Add to dashboard Cite

show abstract

“…Low levels of GM2 storage may affect developing neurons and glial cells, greatly restricting the time window available for effective therapeutic interventions. Indeed, neurodevelopmental defects have been described in GM2 gangliosidosis [38][39][40] as well as other infantile neurodegenerative LSDs; e.g., mucopolysaccharidosis type 1 (MPSI), Nieman-Pick disease 41,42 and globoid cell leukodystrophy (GLD) 43,44 . In addition to the timing of the intervention, the threshold concentration of enzyme needed for a therapeutic effect is a central issue for consideration.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis

Sala

Ornaghi

Morena

et al. 2022

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

“…Low levels of GM2 storage may affect developing neurons and glial cells, greatly restricting the time window available for effective therapeutic interventions. Indeed, neurodevelopmental defects have been described in GM2 gangliosidosis (37)(38)(39) as well as other infantile neurodegenerative LSDs, e.g., Mucopolysaccharidosis type 1 (MPSI) and Nieman-Pick (40,41), and globoid cell leukodystrophy (GLD) (42,43). Further to the timing of the intervention, the threshold concentration of enzyme needed for therapeutic effect is a central issue for consideration.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis

Sala

Ornaghi

Morena

et al. 2021

Preprint

View full text Add to dashboard Cite

The GM2 gangliosidoses Tay-Sachs disease and Sandhoff disease (SD) are respectively caused by mutations in the HEXA and HEXB genes encoding the α and β subunits of β-N-acetylhexosaminidase (Hex). The consequential accumulation of ganglioside in the brain leads to severe and progressive neurological impairment. There are currently no approved therapies to counteract or reverse the effects of GM2 gangliosidosis. Adeno-associated vector (AAV)-based investigational gene therapy (GT) products have raised expectations but come with safety and efficacy issues that need to be addressed. Thus, there is an urgent need to develop novel therapies targeting the CNS and other affected tissues that are appropriately timed to ensure pervasive metabolic correction and counteract disease progression. In this report, we show that the sequential administration of lentiviral vector (LV)-mediated intracerebral (IC) GT and bone marrow transplantation (BMT) in pre-symptomatic SD mice provide a timely and long-lasting source of the Hex enzyme in the central and peripheral nervous systems and peripheral tissues, leading to global rescue of the disease phenotype. Combined therapy showed a clear therapeutic advantage compared to individual treatments in terms of lifespan extension and normalization of the neuroinflammatory and neurodegenerative phenotypes of the SD mice. These benefits correlated with a time-dependent increase in Hex activity and a remarkable reduction in GM2 storage in the brain tissues that single treatments failed to achieve. Our results highlight the complementary and synergic mode of action of LV-mediated IC GT and BMT, clarify the relative contribution of treatments to the therapeutic outcome, and inform on the realistic threshold of enzymatic activity that is required to achieve a significant therapeutic benefit, with important implications for the monitoring and interpretation of ongoing experimental therapies, and for the design of more effective treatment strategies for GM2 gangliosidosis.

show abstract

Prenatal Diagnosis of the Hurler Syndrome: Mucopolysaccharide Pattern in Amniotic Fluid

Cited by 6 publications

References 4 publications

Prenatal Diagnosis of Inborn Errors of Metabolism

Prenatal Diagnosis of Inborn Errors of Metabolism

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis

Contact Info

Product

Resources

About